




RealRate

PHARMACEUTICAL 2018

Ernexa Therapeutics Inc
Rank 207 of 332



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 38% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	9,638
Cost of Goods Sold	0
Intangible Assets	1,004
Liabilities, Current	10,747
Liabilities, Non-Current	52
Other Assets	2,250
Other Compr. Net Income	122
Other Expenses	7,155
Other Liabilities	235
Other Net Income	391
Other Revenues	21,274
Property and Equipment	3,678
Research and Development	0
Selling, General and Administrative Expense	15,587

Output Variable	Value in 1000 USD
Assets	16,570
Liabilities	11,034
Expenses	22,742
Revenues	21,274
Stockholders Equity	5,536
Net Income	-1,077
Comprehensive Net Income	-1,016
BaseVar	36,066
ECR before Limited Liability	80%
Economic Capital Ratio	214%